MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Dr.Reddy's Laboratories Ltd Company Profile (NYSE:RDY)

Consensus Ratings for Dr.Reddy's Laboratories Ltd (NYSE:RDY) (?)
Ratings Breakdown: 1 Sell Rating(s), 3 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for Dr.Reddy's Laboratories Ltd (NYSE:RDY)
Show:
DateFirmActionRatingPrice TargetActions
5/2/2016Goldman SachsInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2016Credit AgricoleUpgradeUnderperform -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/2/2015Deutsche BankInitiated CoverageSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015Citigroup Inc.DowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015BarclaysDowngradeOverweight -> Equal WeightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/29/2015Credit SuisseDowngradeOutperform -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Dr.Reddy's Laboratories Ltd (NYSE:RDY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/12/2016Q416$0.07$2.41 billion$567.00 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/9/2016Q316$0.51$2.48 million$599.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015Q116$0.65$2.54 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q415$0.49$559.00 million$621.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/29/2015Q315$0.53$561.00 million$610.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2014Q115$0.54$474.00 million$486.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q414$0.52$0.47$557.00 million$580.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2014Q314$0.45$0.59$558.20 million$571.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q214$0.46$0.65$561.00 million$537.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2013Q413$0.43$0.40$551.40 million$478.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2013$0.60ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/14/2013Q313$0.40$505.00 million$522.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Dr.Reddy's Laboratories Ltd (NYSE:RDY)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Dr.Reddy's Laboratories Ltd (NYSE:RDY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Dr.Reddy's Laboratories Ltd (NYSE:RDY)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Dr.Reddy's Laboratories Ltd (NYSE:RDY)
DateHeadline
06/20/16 05:49 PMStrong Buy Calls Count For Dr. Reddy's Laboratories Ltd (NYSE:RDY) At 0 - Investor Newswire
06/14/16 10:51 AMDr. Reddy's Laboratories Ltd. (NYSE:RDY) Buying Eight Drugs From Teva Pharmaceutical Industries (NYSE:TEVA ... - KC Register
06/13/16 05:38 PMTrend Of Rating Given To Dr. Reddy's Laboratories Ltd (NYSE:RDY) - Investor Newswire
06/11/16 08:56 AMDr. Reddy’s to Buy Generics From Allergan, Teva for $350 Million -
06/11/16 08:56 AMDr. Reddy's to acquire product portfolio from TEVA for US Market - Business Wire (press release)
06/11/16 08:26 AMDr. Reddy’s to acquire product portfolio from TEVA for US Market - [Business Wire] - HYDERABAD, India & PRINCETON, N.J--(BUSINESSWIRE)-- Dr. Reddy’s Laboratories (BSE:500124, NSE:DRREDDY, NYSE:RDY) has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. (NYSE and ...
06/10/16 06:22 PMDr. Reddy's Laboratories Ltd Co (RDY) Ownership Decreased by BNP Paribas Investment Partners S.A. - Finance Daily
06/01/16 02:33 AMPromius Pharma Launches Sernivo™ (betamethasone dipropionate) Spray, 0.05% New Product For Mild to Moderate Plaque Psoriasis - [at noodls] - Microsoft Word - FINAL Press Release - Promius Pharma Launches Sernivo (2).docx Press Release CONTACT INVESTOR RELATIONS MEDIA RELATIONS KEDAR UPADHYE [email protected](Ph: +91-40-66834297)... This is ...
06/01/16 01:48 AMPromius Pharma Launches Sernivo™ (betamethasone dipropionate) Spray, 0.05% - [Business Wire] - HYDERABAD, India & PRINCETON, N.J.--(BUSINESSWIRE)-- Dr. Reddy’s Laboratories announced today that its US subsidiary, Promius Pharma, LLC, U.S. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), launched Sernivo™ (betamethasone dipropionate) Spray, 0.05% in the U.S. Sernivo Spray, a prescription topical steroid approved by the Food and Drug Administration (FDA) in February of 2016, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. “We are proud to bring Sernivo Spray to patients across the U.S.,” said Raghav Chari, Executive Vice President, Proprietary Products Group at Dr. Reddy’s Laboratories. Promius has conducted two multi-center, randomized, double-blind, vehicle-controlled clinical trials in subjects aged 18 years and older with moderate plaque psoriasis to evaluate the safety and efficacy of Sernivo Spray.
05/26/16 11:10 PMDr. Reddy's (RDY) Acquires Ducere Pharma's OTC Brands - Nasdaq - Financial ExpressDr. Reddy's (RDY) Acquires Ducere Pharma's OTC BrandsNasdaqDr. Reddy's Laboratories Ltd . RDY announced that it acquired a portfolio of over-the-counter (OTC) brands in the cough-and-cold, pain and dermatology categories from Ducere Pharma. The brands acquired include Doans, Bufferin, Nupercainal ointmnent, ...Dr. Reddy's Enters the Branded Consumer Health Arena Through the Acquisition of Six OTC BrandsBusiness Wire (press release)all 23 news articles »
05/26/16 02:57 PMDr. Reddy's (RDY) Acquires Ducere Pharma's OTC Brands -
05/25/16 05:47 AMDr. Reddy’s Enters the Branded Consumer Health Arena Through the Acquisition of Six OTC Brands - [Business Wire] - HYDERABAD, India & PRINCETON, N.J.--(BUSINESSWIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced the acquisition of an eminent portfolio of over-the-counter (OTC) ...
05/23/16 04:43 PMXenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium -
05/20/16 10:59 PMRevenue Update on Dr.Reddy's Laboratories Ltd (ADR)(NYSE:RDY) - Trade Calls - Revenue Update on Dr.Reddy's Laboratories Ltd (ADR)(NYSE:RDY)Trade CallsDr.Reddy's Laboratories Ltd (ADR)(NYSE:RDY) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-market on May 12, 2016. Company reported revenue of $566.97M. Analysts estimated a revenue of $2.44B.
05/20/16 11:03 AMETF’s with exposure to Dr. Reddy’s Laboratories Ltd. : May 20, 2016 -
05/18/16 05:53 PMGoldman Sachs Initiates Coverage on Dr.Reddy's Laboratories Ltd (ADR) to Neutral - Trade Calls - Goldman Sachs Initiates Coverage on Dr.Reddy's Laboratories Ltd (ADR) to NeutralTrade CallsGoldman Sachs Initiates Coverage on Dr.Reddy's Laboratories Ltd (ADR)(NYSE:RDY). The shares have been rated Neutral. The rating by Goldman Sachs was issued on May 2, 2016. In a different note, On Feb 10, 2016, CLSA said it Upgrades its rating on ...
05/18/16 09:25 AMIndia eyes oil-for-drugs deal with Venezuela to recoup pharma cash -
05/17/16 02:52 PMDr. Reddy’s Laboratories Ltd. :RDY-US: Earnings Analysis: Q4, 2016 By the Numbers -
05/14/16 05:32 PMTwo Stocks within Analysts Review: Kindred Healthcare, Inc. (NYSE:KND) , Dr. Reddy's Laboratories Ltd (NYSE:RDY) - Street Updates - Two Stocks within Analysts Review: Kindred Healthcare, Inc. (NYSE:KND) , Dr. Reddy's Laboratories Ltd (NYSE:RDY)Street UpdatesDr. Reddy's Laboratories Ltd (NYSE:RDY) showed bullish move with gain of +0.72% after exchanging volume of 425.84 thousand shares in last trading session ended on 5/13/2016. The company recent traded volume was higher than its average volume of ...and more »
05/13/16 06:11 PMHot Stock to Track: Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY) - The Point Review - The Point ReviewHot Stock to Track: Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY)The Point ReviewDr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY) shares traded during its most recent trading session in the range of $42.17 – $44.14. The stock has slipped -0.74% in the past week and plunged -6.36% in the last 4 weeks, historically the stock illustrate ...Dr. Reddy's (RDY) Q4 Earnings & Revenues Decline Y/YYahoo Newsall 51 news articles »
05/13/16 08:31 AMDr. Reddy's (RDY) Q4 Earnings & Revenues Decline Y/Y -
05/13/16 04:35 AMDr. Reddy's Laboratories (RDY) Q4 2016 Results - Earnings Call Transcript - Seeking Alpha - Dr. Reddy's Laboratories (RDY) Q4 2016 Results - Earnings Call TranscriptSeeking AlphaLadies and gentlemen, good day and welcome to Dr. Reddy's Laboratories Limited Q4 FY 2016 and Fiscal 2016 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask ...
05/12/16 06:18 PMDr. Reddy's Laboratories Limited: Dr. Reddy's Q4 and FY16 Financial Results - The Wall Street Transcript - Dr. Reddy's Laboratories Limited: Dr. Reddy's Q4 and FY16 Financial ResultsThe Wall Street TranscriptHyderabad, India, May 12, 2016: Dr. Reddy's Laboratories Ltd. (NYSE: RDY | BSE: 500124 | NSE: DRREDDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2016 under International Financial Reporting ...and more »
05/12/16 10:17 AMDr. Reddy’s Q4 and FY16 Financial Results - [at noodls] - 95dfc5e9-efc6-4995-ae41-ffe7be67ed95.pdf Press Release CONTACT INVESTOR RELATIONS MEDIA RELATIONS KEDAR UPADHYE [email protected](Ph: +91-40-66834297) ... This is an abstract of the original noodl. To ...
05/12/16 09:44 AMIndia's Dr Reddy's sees more challenges in U.S. business -
05/11/16 11:29 PMDr. Reddy's Laboratories Announces the Appointment of Mr. Bharat Doshi as an Additional Independent Director on the ... - Business Wire (press release) - Dr. Reddy's Laboratories Announces the Appointment of Mr. Bharat Doshi as an Additional Independent Director on the ...Business Wire (press release)He is also an Independent Director of Godrej Consumer Products Limited. About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and ...and more »
05/11/16 12:14 PMDr. Reddy’s Laboratories Announces the Appointment of Mr. Bharat Doshi as an Additional Independent Director on the Board of the Company - [Business Wire] - HYDERABAD, India--(BUSINESSWIRE)-- Mr. Bharat Doshi has been appointed as an Additional Independent Director on the Board of Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), effective May 11, 2016. Mr. Bharat Doshi is a Fellow Member of the Institute of Chartered Accountants of India and of the Institute of Company Secretaries of India, and holds a Master’s degree in Law from Bombay University. Mr. Doshi is a former Executive Director and Group CFO of Mahindra & Mahindra Limited, the flagship company of the Mahindra Group.
05/11/16 04:26 AMDr.Reddy's Laboratories Ltd (RDY) to Release Earnings on Thursday - Washington News Wire - Washington News WireDr.Reddy's Laboratories Ltd (RDY) to Release Earnings on ThursdayWashington News WireDr.Reddy's Laboratories Ltd (NYSE:RDY) is scheduled to announce its Q416 earnings results on Thursday, May 12th. Shares of Dr.Reddy's Laboratories Ltd (NYSE:RDY) opened at 43.53 on Wednesday. The stock has a 50 day moving average of $45.44 and ...Dr.Reddy's Laboratories Ltd (RDY) to Release Quarterly Earnings on ThursdayNewsWay 21Could Dr.Reddy's Laboratories Ltd (ADR) Increase Even More? The Stock Just Had a Gap UpFranklin Independentall 7 news articles »
05/07/16 05:29 PMSignificant Movements: Molina Healthcare Inc (NYSE:MOH) , Dr. Reddy's Laboratories Ltd (NYSE:RDY) - Street Updates - Significant Movements: Molina Healthcare Inc (NYSE:MOH) , Dr. Reddy's Laboratories Ltd (NYSE:RDY)Street UpdatesSignificant Movements: Molina Healthcare Inc (NYSE:MOH) , Dr. Reddy's Laboratories Ltd (NYSE:RDY) - Share on Facebook Share Share on TwitterTweet Share on Google Plus Share Share on Pinterest Share Share on LinkedIn Share Share on Digg Share ...and more »
05/05/16 11:38 PMBroker Outlook For Dr. Reddy's Laboratories Ltd (NYSE:RDY) - Share Trading News - Broker Outlook For Dr. Reddy's Laboratories Ltd (NYSE:RDY)Share Trading NewsBroker Outlook For Dr. Reddy's Laboratories Ltd (NYSE:RDY). By Brenton Akerman / in US Broker Ratings / on Thursday, 05 May 2016 02:44 PM / 0 Comments. The most recently updated broker views and price targets issued for Dr. Reddy's Laboratories Ltd ...
05/05/16 06:30 PMTraders Targeted Movers: Acadia Healthcare Company, Inc. (NASDAQ:ACHC) , Dr. Reddy's Laboratories Ltd (NYSE ... - Street Updates - Traders Targeted Movers: Acadia Healthcare Company, Inc. (NASDAQ:ACHC) , Dr. Reddy's Laboratories Ltd (NYSE ...Street UpdatesDr. Reddy's Laboratories Ltd (NYSE:RDY) moved in red zone with decline of -1.32 points or -2.95% to $43.39. The company has a market worth of $7.40B.Total 248.47 thousand shares were exchanged in last trading session as opposed to average volume of ...
05/02/16 06:36 PMGoldman Sachs Sees 8% Upside At Dr. Reddy's - Benzinga - BenzingaGoldman Sachs Sees 8% Upside At Dr. Reddy'sBenzingaGoldman Sachs has started Dr.Reddy's Laboratories Ltd (ADR) (NYSE: RDY) with a Neutral rating; its price target of Rs.3,334.00 represents an upside of 8 percent. "[W]e believe upside from current levels will depend more on when the company can resolve ...
04/27/16 06:26 PMRecently Changed Price Targets On Dr. Reddy's Laboratories Ltd (NYSE:RDY) - Risers & Fallers - Recently Changed Price Targets On Dr. Reddy's Laboratories Ltd (NYSE:RDY)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY). Most recent broker ratings. 02/10/2016 – Dr. Reddy's Laboratories Ltd was upgraded to “buy” by analysts at Credit Agricole.
04/26/16 06:28 PMDr. Reddy's Laboratories Limited: Earnings Call Notification - The Wall Street Transcript - Dr. Reddy's Laboratories Limited: Earnings Call NotificationThe Wall Street TranscriptAbout Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (NYSE: RDY NSE: DRREDDY; BSE: 500124) is an integrated pharmaceutical company, committed to accelerating access to providing affordable and innovative medicines for healthier lives. Through its three ...and more »
04/26/16 08:08 AMEarnings Call Notification - [at noodls] - Dr Reddy's Q4 FY16 v1 Press Release CONTACT INVESTOR RELATIONS MEDIA RELATIONS KEDAR UPADHYE [email protected](Ph: +91-40-66834297) ... This is an abstract of the original noodl. To continue reading ...
04/26/16 06:34 AMDr. Reddy's to Release Q4 and Full Year FY16 Results on May 12, 2016; Earnings Call Slated for May 12, 6.30 PM IST / 9.00 AM EDT - [Business Wire] - Dr. Reddy's Laboratories will announce results for the Fourth Quarter and Full Year ended March 31, 2016 on Thursday, May 12, 2016 after the Board Meeting.
04/25/16 06:15 AMManagement Council - [at noodls] - Our ensures that everything we do leads to perfect alignment - between our purpose of addressing patients' needs, and our business goals. Consisting of senior management members from various functions, ...
04/24/16 06:52 PMNext Weeks Broker Price Targets For Dr. Reddy's Laboratories Ltd (NYSE:RDY) - Share Trading News - Next Weeks Broker Price Targets For Dr. Reddy's Laboratories Ltd (NYSE:RDY)Share Trading NewsDr. Reddy's Laboratories Ltd has a 50 day moving average of 46.38 and a 200 day moving average of 49.10. The stock's market capitalization is 8.10B, it has a 52-week low of 40.67 and a 52-week high of 68.00. The share price of the company (NYSE:RDY) ...
04/23/16 06:03 PMDr. Reddy's Laboratories Ltd (NYSE:RDY) Has Been Given An ABR Of 3.5 - Investor Newswire - Dr. Reddy's Laboratories Ltd (NYSE:RDY) Has Been Given An ABR Of 3.5Investor NewswireAnalysts have a positive outlook on Dr. Reddy's Laboratories Ltd (NYSE:RDY) stock. As of 2016-04-23, the stock has been placed an ABR of 3.5. This number comes on a scale of 1 to 5, where one suggests a strong buy call and five indicates Strong Sell.and more »
04/22/16 06:34 PMDr. Reddy's Laboratories Ltd (NYSE:RDY) Latest Broker Coverage - Risers & Fallers - Dr. Reddy's Laboratories Ltd (NYSE:RDY) Latest Broker CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY). According to the latest broker reports outstanding on Friday 22nd of April, 0 analysts have a rating of “strong buy”, 0 ...
04/19/16 04:12 AMZEMBRACE™ SymTouch™ (Sumatriptan Injection) 3 mg, Approved by the FDA in January 2016 for the Acute Treatment of Migraine with or without Aura in Adults, is Now Commercially Available in the U.S. - [Business Wire] - HYDERABAD, India & PRINCETON, N.J.--(BUSINESSWIRE)-- Promius Pharma LLC, a subsidiary of Dr. Reddy’s Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced today that ZEMBRACE SymTouch is now commercially available in the U.S. ZEMBRACE SymTouch is a prefilled, low-dose, ready-to-use, 2-step autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. Because ZEMBRACE SymTouch is a subcutaneous injection, it may lead to rapid relief of migraine.
04/08/16 11:51 PMUpgrades And Downgrades For Dr. Reddy's Laboratories Ltd (NYSE:RDY) - Risers & Fallers - Upgrades And Downgrades For Dr. Reddy's Laboratories Ltd (NYSE:RDY)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY). The latest broker reports which are currently outstanding on Friday 8th of April state 0 analysts have a rating of “strong buy”, ...
04/07/16 11:28 AMChina Takes a Breather as India Drives Growth in Asia -
04/06/16 11:40 PMCurrent Price Targets For Dr. Reddy's Laboratories Ltd (NYSE:RDY) - Risers & Fallers - Current Price Targets For Dr. Reddy's Laboratories Ltd (NYSE:RDY)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY). The latest broker reports which are currently outstanding on Wednesday 6th of April state 0 analysts have a rating of “strong buy ...
04/06/16 09:00 AMHow Did Indian Equities React to the RBI’s Repo Rate Cut in April 2016? -
04/05/16 12:18 PMInvesting in Indian Stocks: Active versus Passive Modes -
04/05/16 05:00 AMCutispharma, Dr. Reddy's Laboratories Announce Partnership - [PR Newswire] - WILMINGTON, Mass., April 5, 2016 /PRNewswire/ -- CutisPharma, a specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications, ...
04/01/16 06:19 PMNew Analyst Ratings On Dr. Reddy's Laboratories Ltd (NYSE:RDY) - Risers & Fallers - New Analyst Ratings On Dr. Reddy's Laboratories Ltd (NYSE:RDY)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY). The latest broker reports which are currently outstanding on Friday 1st of April state 0 analysts have a rating of “strong buy”, ...and more »
04/01/16 11:08 AMEmerging Consumer Shopping Up 30%, Survey Says -
04/01/16 08:40 AMDr. Reddy's Acquires Anticancer Drug Rights from Eisai -
About Dr.Reddy's Laboratories Ltd

Dr.ReddyDr. Reddy's Laboratories Limited is an integrated global pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Global Generics segment consists of its business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates, also known as API or bulk drugs. Proprietary Products segment consists of its differentiated formulations business, its new chemical entities (NCEs) business, and its dermatology focused specialty business operated through Promius Pharma.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: RDY
  • CUSIP:
Key Metrics:
  • Previous Close: $47.24
  • 50 Day Moving Average: $45.29
  • 200 Day Moving Average: $45.12
  • P/E Ratio: 27.20
  • P/E Growth: 2.53
  • Market Cap: $8.06B
  • Current Quarter EPS Consensus Estimate: $2.05 EPS
Additional Links:
Dr.Reddy's Laboratories Ltd (NYSE:RDY) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha